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Abstract
Motivation: Computational drug repositioning is a cost-effective strategy to identify novel indica-
tions for existing drugs. Drug repositioning is often modeled as a recommendation system problem.
Taking advantage of the known drug–disease associations, the objective of the recommendation sys-
tem is to identify new treatments by filling out the unknown entries in the drug–disease association
matrix, which is known as matrix completion. Underpinned by the fact that common molecular path-
ways contribute to many different diseases, the recommendation system assumes that the underly-
ing latent factors determining drug–disease associations are highly correlated. In other words, the
drug–disease matrix to be completed is low-rank. Accordingly, matrix completion algorithms effi-
ciently constructing low-rank drug–disease matrix approximations consistent with known associa-
tions can be of immense help in discovering the novel drug–disease associations.
Results: In this article, we propose to use a bounded nuclear norm regularization (BNNR) method to
complete the drug–disease matrix under the low-rank assumption. Instead of strictly fitting the
known elements, BNNR is designed to tolerate the noisy drug–drug and disease–disease similarities
by incorporating a regularization term to balance the approximation error and the rank properties.
Moreover, additional constraints are incorporated into BNNR to ensure that all predicted matrix entry
values are within the specific interval. BNNR is carried out on an adjacency matrix of a heteroge-
neous drug–disease network, which integrates the drug–drug, drug–disease and disease–disease
networks. It not only makes full use of available drugs, diseases and their association information,
but also is capable of dealing with cold start naturally. Our computational results show that BNNR
yields higher drug–disease association prediction accuracy than the current state-of-the-art methods.
The most significant gain is in prediction precision measured as the fraction of the positive predic-
tions that are truly positive, which is particularly useful in drug design practice. Cases studies also
confirm the accuracy and reliability of BNNR.
Availability and implementation: The code of BNNR is freely available at https://github.com/
BioinformaticsCSU/BNNR.
Contact: jxwang@mail.csu.edu.cn
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
The process of new drug discovery is time-consuming and tremen-
dously expensive (Chong et al., 2007). It has been showed that the
average time of developing a new drug is more than 13.5 years and
the cost exceeds $1.8 billion dollars (Paul et al., 2010). Discovering
new and reliable indications for commercialized drugs allows the
pharmaceutical industry and the research community to reduce time
and costs, because the existing commercialized drugs have already
owned safety, efficacy and toleration data after various tests and
clinical trials. The process of identifying new applications for exist-
ing drugs is known as drug repositioning. In fact, some successfully
repositioned drugs, such as sildenafil, raloxifene and thalidomide,
have generated generous revenues for their patent holders or compa-
nies. Therefore, drug repositioning is an effective strategy for devel-
oping new drugs.
Computational drug repositioning has attracted increasing attention,
since manual investigation is time-consuming. With the development of
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high throughput technology and continuously updating databases, quite
a few computational approaches have been proposed, including
network-based analysis, machine learning, text mining and semantic in-
ference approaches. The network-based methods are popular and fun-
damental for drug repositioning. Based on a network of drugs, diseases
and targets (proteins), Martinez et al. (2015) proposed an approach
named DrugNet to predict new use for existing drugs. DrugNet can per-
form both drug–disease and disease–drug prioritization by propagating
information in the heterogeneous network. Gottlieb et al. (2011) inte-
grated drug similarities and disease similarities to obtain primary fea-
tures to support a computational approach called PREDICT to identify
unknown drug–disease associations. Wang et al. (2013) constructed a
heterogeneous drug–target graph, which contains intra-similarity infor-
mation and drug–target association information. Based on the guilt-
by-association principle, heterogeneous graph based inference (HGBI)
algorithm (Wang et al., 2013) was proposed to predict new drug–target
associations. HGBI is also used for predicting drug–disease associations
(Wang et al., 2014). Luo et al. (2016) exploited the available informa-
tion of drug–disease associations to enhance drug similarity and disease
similarity. The MBiRW algorithm, which used some comprehensive
similarity measures and Bi-Random Walk (BiRW) algorithm, is imple-
mented on the drug–disease heterogeneous network to predict potential
drug–disease associations.
Matrix factorization and matrix completion techniques have
been applied to drug repositioning in recent years. Dai et al. (2015)
incorporated the interaction network of genes and developed a ma-
trix factorization model. Taking advantage of the information in
genes network, the association between drug and disease can be pre-
dicted and new indications for known drugs can be obtained. Luo
et al. (2018) constructed a heterogeneous network by integrating
drug–drug network, disease–disease network and drug–disease asso-
ciation network, and then R4SVD (Li and Yu, 2017) was employed
to efficiently compute the dominant singular values and the corre-
sponding singular vectors of the association matrix. Based on the
Singular Value Thresholding (SVT) algorithm (Cai et al., 2010), a
Drug Repositioning Recommendation System (DRRS) has been pro-
posed to rank the potential associations between drugs and diseases
by completing the drug–disease association matrix. In fact, the
methods based on random walks are equivalent to certain special
cases of those using matrix completions. For example, MBiRW is
equivalent to finding the eigenvector with respect to the largest
eigenvalue of the association matrix. However, the above matrix
completion algorithms are operated in a noiseless setting, assuming
that the drug–disease associations are correctly derived and the dis-
ease–disease as well as drug–drug similarities are accurately meas-
ured. But in reality, drugs and diseases vary in many aspects and it is
difficult to construct a single measure to precisely describe the simi-
larity relationship among drugs or diseases. Occasionally, such simi-
larity is misleading. For example, a disease caused by bacteria may
have highly similar symptoms as one caused by virus, which should
be treated by completely different drugs. Moreover, in the matrix
completions algorithms, typically, 1’s in the drug–disease associ-
ation matrix denote known drug–disease associations while 0’s rep-
resent the unknowns. The predicted values are expected to be within
the range of [0, 1], indicating the likeliness of the predicted associa-
tions. However, the above matrix factorization and completion
approaches are unable to avoid the situations that the predicted val-
ues fall out of the [0, 1] range, which brings difficulty in biological
interpretation.
In this study, assuming that similar drugs share the similar mo-
lecular pathway to treat similar diseases, we consider the prediction
of drug–disease association as a noisy matrix completion problem
and develop a bounded nuclear norm regularization (BNNR)
method to address this problem. First of all, we construct a heteroge-
neous drug–disease network, which is composed of drug–drug,
drug–disease and disease–disease sub-networks. Then, BNNR is
implemented to recover the missing entries in the adjacency matrix
of this heterogeneous network while tolerating the potential noise in
drug–drug and disease–disease similarities calculations. Finally, we
evaluate the performance of BNNR on various datasets and com-
pare it with several state-of-the-art methods. Our results show that
our approach has superior capability of predicting hidden drug–dis-
ease associations. The main contributions of our BNNR model
include:
• BNNR performs noisy matrix completion by incorporating nu-
clear norm regularization, which effectively addresses overfitting
and leads to better improved accuracy as shown in our results;
• Our BNNR model incorporates a range constraint, which enfor-
ces all predicted matrix entry values within the specific interval;
• Our BNNR model is able to deal with noisy data efficiently; and
• An efficient iterative scheme is designed to numerically solve the
BNNR model.
2 Materials and methods
In this section, we describe the BNNR model to predict the potential
indications for existing drugs, which is organized as follows. First,
we describe the datasets used in this study. Then, we depict the con-
struction of the drug–disease heterogeneous network and its adja-
cency matrix to be completed. Finally, we present the BNNR model,
solved by alternating direction method of multipliers (ADMM), to
fill out the unknown associations between drugs and diseases. The
overall workflow of BNNR is illustrated in Figure 1.
2.1 Datasets
We use the gold standard dataset to predict new drug indications,
which is obtained from (Gottlieb et al., 2011) collecting comprehen-
sive associations from multiple data sources. There are 593 drugs,
313 diseases and 1933 validated drug–disease associations. Drugs
are collected from the DrugBank database (Wishart et al., 2006) and
diseases are extracted from the Online Mendelian Inheritance in
Man (OMIM) dataset (Ada et al., 2002).
Fig. 1. The overall workflow of BNNR. (a) Drug–drug network and its similarity
matrix. (b) Disease–disease network and its similarity matrix. (c) Drug–dis-
ease association network and its association matrix. (d) The heterogeneous
drug–disease network and its adjacency matrix. (e) The model of BNNR
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The similarities between drugs are calculated by the Chemical
Development Kit (CDK) (Steinbeck et al., 2003) according to the chem-
ical structures of all drug compounds in the Canonical Simplified
Molecular Input Line-Entry System (SMILES) (Weininger, 1988). We
firstly download the Canonical SMILES format of all drugs from
DrugBank. Then, we utilize CDK to calculate a binary fingerprint for
each drug. Finally, the Tanimoto score (Tanimoto, 1958) measuring
the similarity of pairwise drugs is calculated with respect to their chem-
ical fingerprints, which is in the range of [0, 1].
Disease–disease similarities are obtained from MimMiner (Van
Driel et al., 2006), which measure the number of appearance of
MeSH (medical subject headings vocabulary) terms of two diseases
in the medical descriptions obtained from the OMIM database.
2.2 Construction of the heterogeneous network
We construct a heterogeneous drug–disease network, which integra-
tes the drug–drug, disease–disease and drug–disease association net-
works. Let R ¼ fr1; r2; :::; rmg and D ¼ fd1;d2; :::; dng denote a set
of m drugs and n diseases, respectively. For the drug–drug network,
the edge between two drugs is weighted by the pairwise drug simi-
larity value. Similarly, the edge between two diseases is weighted by
the pairwise disease similarity value. Then, the drug–disease associ-
ation network is treated as a bipartite graph G(R, D, E), where
EðGÞ ¼ feijg  RD contains edges representing known associa-
tions between drug ri and disease dj. In this heterogeneous drug–dis-
ease network, drug–drug network and disease–disease network are
connected by drug–disease associations. Figure 1a–d illustrates the
construction of the heterogeneous network.
The adjacency matrix of the drug–disease heterogeneous net-
work is then defined as:






where the sub-matrices ARR and ADD denote the adjacency matrices
of drug network and disease network and their weights are set as the
pairwise drug and disease similarities, respectively, in range [0, 1].
ARR and ADD are dense which include rich correlation information
among drugs and diseases. In contrast, due to the fact that drug–dis-
ease associations are rare, ADR is usually extremely sparse, where
1’s denote known drug–disease associations and 0’s correspond to
the unknowns. After all, our goal is to fill out the unknown elements
in ADR as the predicted scores of potential associations between
drugs and diseases.
2.3 BNNR for predicting drug–disease associations
Assuming a low-rank structure, the general matrix completion prob-






where M 2 RðmþnÞðmþnÞ is the given incomplete matrix, rank(.)
denotes the rank function, X is a set containing index pairs (i, j) of
all known entries in M and PX is the projection operator onto X.
ðPXðXÞÞij ¼
Xij; ði; jÞ 2 X
0; ði; jÞ 62 X :

Unfortunately, the rank minimization problem is known to be
NP-hard. The rank minimization in the above matrix completion





s:t:PX Xð Þ ¼ PX Mð Þ;
(1)
where kXk denotes the nuclear norm of X, which is defined as the
sum of all singular values of X. The nuclear norm minimization
model is a convex optimization problem. Many algorithms have
been designed to provide numerical solutions for the above model or
alternative forms, including the fixed point continuation with ap-
proximate SVD (FPCA) (Ma et al., 2011), the accelerated proximal
gradient algorithm (APG) (Toh et al., 2010), the SVT algorithm (Cai
et al., 2010) and the ADMM (Boyd et al., 2011; Chen et al., 2012;
Wen et al., 2010). Candes et al. (2013) showed that the solution
obtained by optimizing the nuclear norm is equivalent to the one by
rank minimization under certain conditions, minimizing the nuclear
norm.
For predicting drug–disease associations, the elements in the
drug similarity matrix ARR and disease similarity matrix ADD are
within the interval of [0, 1]. The elements in the association matrix
ARD are either 0 or 1. As a result, the predicted values in the un-
known entries are expected to be in the interval of [0, 1], where a
predicted value closer to 1 indicates that this is likely to be an indica-
tion and vice versa. Nevertheless, in the above matrix completion
models (1), the entries in the completed matrix can be any real value
in (1, þ1). A predicted value out of the interval [0, 1] is mean-
ingless in the application context. Hence, it is important to add a
bound constraint to the matrix completion model to ensure that the
uncovered missing elements are within the interval of [0, 1].
Moreover, since there may be a lot ‘noise’ in the drug and disease
data, particularly when measuring the drug–drug and disease–
disease similarities, the drug repositioning model should effective





s:t:jjPXðXÞ  PXðMÞjjF  ;
where  measures the noise level. However, for this model with the
inequality constraint, choosing the appropriate parameter is chal-
lenging, because the noise level is not explicitly known. Moreover, it
is not straightforward to come up with an efficient solver for this
model. Therefore, we relax the constraint satisfaction model into a
regularization model. Introducing the soft regularization term not
only enables tolerance to the unknown noise (Chen et al., 2012;
Hu et al., 2013; Ma et al., 2011; Toh et al., 2010), but also provides
computational convenience.
Putting all pieces together, we propose a BNNR method, which
minimizes the nuclear norm as the regularization term and ensures
the recovered matrix elements within a specific interval. The BNNR







s:t: 0  X  1;
(2)
where a is parameter balancing the nuclear norm and the error term.
Note that we use 0  X  1 to denote 0  Xij  1 for all ele-
ments in X throughout this paper. We derive a simple but effective
numerical scheme using ADMM to solve (2).
Model (2) is solved by an iterative method. Starting from the ini-
tial solution X1 ¼ PXðMÞ. It is important to notice that the object-
ive function in (2) is convex. By introducing an auxiliary matrix W,
(2) can be optimized using the ADMM framework in the following
equivalent form.
















0  W  1:
(3)
Accordingly, the augmented Lagrangian function becomes










where Y is the Lagrange multiplier and b>0 is the penalty param-
eter. At the k-th iteration, BNNR requires alternatively
computing Wkþ1; Xkþ1 and Ykþ1.
Compute Wkþ1: We fix Xk and Yk to minimize LðW;Xk;Yk; a;bÞ
for Wkþ1. We hereby take full advantage of the inverse operator to ob-
tain an exact and closed-form solution.














Here, W* is the optimal solution of arg min
W
LðW;Xk;Yk; a; bÞ,
if and only if
aPXðPXðWÞ  PXðMÞÞ  Yk  bðXk WÞ ¼ 0 (6)
holds, where PX denotes the adjoint operator of PX. Then, a closed-
form solution becomes








PXPX Mð Þ þXk
	 



































where I is the identity operator. ðI þ abP

XPXÞ
1 denotes the inverse
operator of ðI þ abP

XPXÞ and is equal to I  aaþbP

XPX (Yang and
Yuan, 2012). It’s worth noting that PXPX ¼ PX. Considering the
interval ½0; 1 constraint, we limit the range of the elements of Wkþ1
to [0, 1] such that
Wkþ1 ¼ Q½0;1ðWÞ; (8)
where Q½0;1 is the projection operator defined as
ðQ½0;1ðWÞÞij ¼
1; Wij > 1
Wij; 0  Wij  1



































where DsðXÞ is the singular value shrinkage operator (Cai et al.,




ðri  sÞuiviT ;
where ri is the singular values of X which is larger than s, while ui
and vi are the left and right singular vectors corresponding to ri,
respectively.
Compute Ykþ1: Finally, Ykþ1 is calculated as









where c is the learning rate, which is set to 1 in this study for simpli-
city (Hu et al., 2013). Putting all pieces together, Algorithm 1
presents an iterative BNNR scheme for solving (2). Based on the as-
sumption that similar diseases tend to be treated by similar drugs,
because of the common molecular pathways, there exist certain low-
rank structures governing drug–disease associations. Minimizing the
nuclear norm of the target matrix, BNNR reveals the low-rank
structures and provides a way to recover the missing entries. After
supplying the adjacency matrix of the drug–disease heterogeneous
network to BNNR, we can obtain an updated drug–disease associ-
ation matrix ADR, where the unknown entries in ADR are filled up.
The entries in ADR with predicted values (scores) close to 1 indicate
the potential drug–disease associations.
3 Results and discussion
3.1 Evaluation metrics
To evaluate the performance of BNNR, a 10-fold cross-validation is
conducted to verify the candidate diseases for given drugs. All
known drug–disease associations are randomly divided into 10 ex-
clusive subsets of approximately equal size. Each subset is treated as
the testing set in turn, while the remaining nine subsets are used as
the training set. The 10-fold cross-validation is repeated 10 times
Algorithm 1. BNNR Algorithm
Input: The drug similarity matrix ARR 2 Rmm, the disease
similarity matrix ADD 2 Rnn, the drug–disease associ-
ation matrix ADR 2 Rnm, parameters a and b.






initialize X1 ¼ PXðMÞ;W1 ¼ X1;Y1 ¼ X1; c ¼ 1; //X is a set






Wkþ1  1b Yk
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with random subset division and the average accuracy values are
showed as the final results.
After the association matrix of the drug–disease heterogeneous
network is completed, the predicted scores of all drug–disease asso-
ciations are obtained. For each drug, the predicted scores of its asso-
ciations with the diseases are ranked in descending order. The score
of the candidate association exceeding a given threshold is consid-
ered as a positive prediction; otherwise, negative. For increasing
threshold values, true positive rate (TPR) and false positive rate
(FPR) will be calculated to generate the receiver-operating character-
istic (ROC) curve. Precision and recall (equivalent to TPR) are
obtained to plot the precision–recall (PR) curve (Davis et al., 2006).
Meanwhile, due to the fact that the top-ranked results are of most
interest, the number of correctly identified drug–disease associations
using different thresholds will be illustrated. The area under the
ROC curve (AUC) and top-ranked results are presented to compare
the overall performance of BNNR with a variety of existing methods
in this study.
3.2 Parameter setting
In BNNR algorithm, there are two parameters needed to be deter-
mined, including a and b. For the parameters a and b, we perform
cross-validation on the training dataset to determine, which are
determined from {0.1, 1, 10, 100}. Table 1 reports AUC values cal-
culated by BNNR when a and b are ranging from {0.1, 1, 10, 100}
in 10-fold cross-validation, where the best AUC values are displayed
in bold. One can find that BNNR achieves the best performance
when a¼1 and b¼10.
Meanwhile, we terminate the BNNR algorithm when the follow-





where fk ¼ kXkþ1XkkFkXkkF , tol1 and tol2 are the given tolerances, which
are set as 2103 and 105 in BNNR algorithm, respectively.
3.3 Compare with other methods
BNNR is compared with four latest methods for drug repositioning:
HGBI (Wang et al., 2013), DrugNet (Martinez et al., 2015),
MBiRW (Luo et al., 2016) and DRRS (Luo et al., 2018). Based on
the guilt-by-association principle and the interpretation of informa-
tion flow, HGBI is designed for predicting disease-associated drugs.
DrugNet is based on propagation flow algorithm, which can per-
form both drug–disease and disease–drug prioritization. MBiRW
and DRRS are our previous works, MBiRW uses comprehensive
similarity measures and BiRW algorithm to infer drug–disease asso-
ciation. DRRS constructs a heterogeneous drug–disease network
and conducts prediction based on the matrix completion of SVT al-
gorithm to predict potential indications for drugs.
Although DRRS and BNNR are based on the same heteroge-
neous drug–disease network, BNNR can exploit more accuracy
association information due to better robustness. BNNR has several
distinct advantages compared with DRRS: First, BNNR could fit the
whole network better. Since the values of similarity matrices com-
puted in silico may include noisy information, BNNR has a relaxed
penalty function to cope with noisy entries, while DRRS attempts to
fit all entries. Second, BNNR has more interpretable predicted val-
ues. The bounded constraint ensures that all predicted associations
are within [0, 1]. In contrast, the predicted association scores may
be negative or >1 in DRRS. Third, the regularization term based on
nuclear norm is able to address overfitting effectively. This enables
us to design an appropriate stop criterion for BNNR to directly ob-
tain the optimal solution without the need of designating a part of
known drug–disease associations as the validation set to identify the
optimal rank.
To ensure a fair comparison, the parameters in the compared
approaches are set to the default values according to the authors’
recommendation (HGBI: a¼0.4; MBiRW: a¼0.3, l ¼ 2, r ¼ 2;
DRRS: s and d are two adaptive parameters) and cross-validation
(DrugNet: a is chosen from {0.1, 0.2, . . ., 0.9}). The overall results
of 10-fold cross-validation for all methods are depicted by ROC
curve, PR curve and top-ranked results in Figure 2. As shown in
Figure 2, the BNNR method outperforms the other methods in
terms of AUC values of the ROC curves, precisions and top-ranked
indications. Specifically, BNNR reports AUC value of 0.932, while
HGBI, DrugNet, MBiRW and DRRS have 0.829, 0.868, 0.917 and
0.930, respectively. The more significant gains are in precision.
BNNR obtains prediction precision of 0.440, which is significantly
higher than HGBI (0.130), DrugNet (0.192), MBiRW (0.304) and
DRRS (0.375). It is important to note that BNNR can successfully
rank 44.0% true drug–disease associations at top 1, which is 13.6
and 6.5% higher than MBiRW and DRRS, respectively. One true
drug–disease association is treated as a retrieved association when
its predicted rank is higher than the specified top rank threshold.
These approaches identify different numbers of true drug–disease
associations with respect to different rank cutoffs, which are pre-
sented in Figure 2c. For instance, among the 1933 true drug–disease
associations, 1333 associations are identified at top 5 by BNNR,
while in comparison, only 561, 738, 1044 and 1251 associations are
predicted by HGBI, DrugNet, MBiRW and DRRS, respectively. In
practice, precision is a more important measure of the drug–disease
association prediction performance, because a more precise predic-
tion provides correct indication for existing drugs with higher prob-
ability, which can lead to budget and time reduction.
3.4 Predicting indications for new drugs
To assess the capability of BNNR in predicting potential indications
for new drugs, we choose these drugs which have only one known
drug–disease association to conduct a de novo test. For each of these
drugs, the known disease association is removed in turn as the test
sample and other existing associations are used as training sample.
For a new drug without any known drug–disease association,
BNNR is able to predict its drug–disease associations by taking ad-
vantage of the similarity information of the novel drug in adjacency
matrix. Also, due to the fact that there is no drug–disease association
information for the novel drug, the similarity information is more
important than the existing drug–disease association information
for the other drugs, which should be given heavier weights.
Equivalently, association matrix is multiplied by a weight coefficient
0.7 in this study.
As shown in Figure 3 for the de novo test, BNNR achieves AUC
value of 0.830, while HGBI, DrugNet, MBiRW and DRRS have
Table 1. The AUC values using different a and b values in 10-fold
cross-validation on the gold standard dataset
a\b 0.1 1 10 100
0.1 0.757 0.785 0.879 0.888
1 0.863 0.921 0.933 0.899
10 0.854 0.921 0.926 0.890
100 0.862 0.919 0.925 0.889
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inferior results with 0.746, 0.782, 0.818 and 0.824, respectively.
For top-ranked results, BNNR outperforms all methods at top 5, 10
and 50, except for being inferior to DRRS at top 1.
3.5 Case studies
In these case studies, we apply BNNR to predict new uses for al-
ready approved drugs in practical applications. In the process of
identifying novel drug–disease associations, we treat all known
drug–disease associations in the gold standard dataset as the training
set and regard the missing drug–disease pairs as the candidate set.
After the prediction scores of all candidate pairs are computed by
BNNR, we rank the candidate diseases by the predicted scores for
each drug.
In order to confirm whether the predicted diseases are true or
not, we choose Levodopa, Doxorubicin, Amantadine and Flecainide
as the representative drugs to validate their potential diseases pre-
dicted by BNNR and then list the confirmed information of top-5
candidate diseases for them. We confirm the potential diseases asso-
ciated with the given drug by authoritative public databases, such as
DrugBank, CTD (Davis et al., 2013) and KEGG (Kanehisa et al.,
2014). The predicted results and the supporting evidences are sum-
marized in Table 2. For each representative drug, more than three
new drug–disease associations on top-5 have been reported in the
public databases. It demonstrates the effectiveness of BNNR in pre-
dicting novel indications for drugs in practical use.
Furthermore, BNNR identifies other new indications including:
Levodopa for hyperplastic myelinopathy; Doxorubicin for dohle
bodies; Amantadine for restless legs syndrome and malignant hyper-
thermia; Flecainide for nephropathy-hypertension and hyperplastic































































































Fig. 2. The performance of all methods in predicting drug–disease association for 10-fold cross-validation. (a) ROC curve of prediction results. (b) PR curve of pre-
dicting candidate diseases for drugs. (c) The number of correctly retrieved drug–disease associations for various rank thresholds





















































Fig. 3. The performance of all methods in predicting potential diseases for
new drugs. (a) PR curve of prediction results. (b) The number of retrieved
drugs for various rank thresholds
Table 2. The top five candidate diseases for Levodopa,
Doxorubicin, Amantadine and Flecainide
Drugs
(DrugBank IDs)





Parkinson disease (168600) KEGG/DB/CTD
Dementia (125320) DB/CTD





Small cell cancer of the lung (182280) CTD
Dohle bodies (223350)
Testicular germ cell tumor (273300) CTD




Parkinson disease (168600) KEGG/DB/CTD
Dementia (125320) DB/CTD
Restless legs syndrome (102300)




Atrial fibrillation (608583) CTD
Cardiac arrhythmia (115000) DB/CTD
Diastolic hypertension (608622) CTD
Nephropathy-hypertension (161900)
Hyperplastic myelinopathy (147530)












myelinopathy. These predicted associations are not yet reported in
current literature, but may have a greater likelihood of existing.
There are great opportunities to research and validate these associa-
tions for medical researchers and pharmaceutical companies.
3.6 The effects of bounded constrain and regularization
model of BNNR on performance
In order to evaluate the effectiveness of bounded constraint [0, 1]
and regularization model, we compare BNNR with two models in
10-fold cross-validation. The first model is BNNR without bounded
constraint [0, 1] (referred to as NNR), while the other one is BNNR







kPXðXÞ  PXðMÞk2F; (12)





0  X  1:
(13)
One can find that incorporating the regularization term leads to
more robust prediction results compared to simply minimizing the
nuclear norm, where the noise in similarity measures is tolerated.
Moreover, constraining the predicted association values within [0, 1]
further improves the prediction accuracy. This is shown in the 10-fold
cross-validation results illustrated in Figure 4.
To further verify the robustness of BNNR, we increasingly add
random noises to the drug–drug and disease–disease similarity
matrices. The noise entries are drawn independently from
Nð0; 1=20Þ and noise rate is the proportion of the contaminated
entries with respect to all components of similarity matrix. We set
the noise rate in [0, 0.3] with an increase step size of 0.06. BNNR
and BNN are compared in 10-fold cross-validation in terms of AUC
values. Without a surprise, as shown in Figure 5, the AUC values de-
crease gradually as the noise rate increases in both BNNR and
BNN. However, the decrease of BNNR is much slower compared to
BNN, indicating that BNNR is able to better tolerate noisy similar-
ity computations. This also explains why BNNR leads to better pre-
diction accuracy when the nuclear norm regularization term is
incorporated.
3.7 Experiments on the other datasets
In order to illustrate the adaptability of BNNR in different datasets, we
perform BNNR on the two other datasets including Cdataset and
DNdataset, which are used in our previous work (Luo et al., 2016,
2018). Cdataset (Luo et al., 2016) contains 663 drugs collected in
DrugBank, 409 diseases obtained in OMIM database and 2352
known drug–disease associations. DNdataset (Martinez et al., 2015)























Fig. 4. Performance comparison of BNNR, NNR and BNN in 10-fold cross-val-
idation in terms of AUC values




















Fig. 5. Performance comparison of BNNR and BNN under different noise
rates in terms of AUC values






























































































Fig. 6. The performance of all methods in predicting drug–disease associations for 10-fold cross-validation on Cdataset. (a) ROC curve of prediction results. (b) PR
curve of predicting candidate diseases for drugs. (c) The number of correctly retrieved drug–disease associations for various rank threshold
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includes 1490 drugs registered in DrugBank, 4516 diseases anno-
tated by Disease Ontology (DO) terms and 1008 known drug–
disease associations. We evaluate the robustness of our method on
these two datasets by performing 10-fold cross-validation and the de
novo test. The parameters of BNNR for Cdataset and DNdataset
are set as Section 3.2. (For Cdataset, a¼1 and b¼10. For
DNdataset, a¼1 and b¼1.)
For Cdataset, as shown in Figure 6, BNNR obtains AUC value
of 0.948 in 10-fold cross-validation, while HGBI, DrugNet,
MBiRW and DRRS have 0.858, 0.903, 0.933 and 0.947, respective-
ly. The PR curves illustrate that BNNR obtains the best precision
with 0.471, while HGBI, DrugNet, MBiRW and DRRS have 0.168,
0.239, 0.351 and 0.403, respectively. Meanwhile, BNNR outper-
forms the other methods on top rank results. More specifically, at
top-5 rank, 1855 associations out of 2532 are identified by BNNR,
while only 796, 1193, 1481 and 1753 associations are predicted by
HGBI, DrugNet, MBiRW and DRRS, respectively. In the de novo
test, PR curve and top rank results are illustrated in Figure 7. BNNR
obtains AUC value of 0.812, while HGBI, DrugNet, MBiRW and
DRRS have 0.732, 0.785, 0.804 and 0.819, respectively. DRRS
achieves slightly better performance than BNNR. In addition,
BNNR outperforms the other methods with respect to different top-
ranked thresholds. Specifically, for 177 drug associations, BNNR
retrieves 87(49.2%) drugs at top 10 rank, while HGBI, DrugNet,
MBiRW and DRRS have 48(27.1%), 61(34.5%), 80(45.2%) and
78(44.0%), respectively.
For DNdataset, as shown in Figure 8, BNNR obtains AUC value
of 0.955 in 10-fold cross-validation, while HGBI, DrugNet,
MBiRW and DRRS have 0.921, 0.950, 0.956 and 0.934, respective-
ly. The PR curves show that BNNR obtains the best precision with
0.347, while HGBI, DrugNet, MBiRW and DRRS have 0.204,
0.150, 0.321 and 0.346, respectively. It is a noteworthy fact that
BNNR has better AUC value and precision compared to other meth-
ods. Meanwhile, BNNR outperforms the other methods on top rank
results from four different thresholds. In de novo test, PR curve and
top rank results of de novo test are illustrated in Figure 9. BNNR
obtains AUC value of 0.956, which is slightly worse than DrugNet
and MBiRW, while HGBI and DRRS have 0.928 and 0.946, respect-
ively. BNNR surpasses the other methods on top rank results: for
347 test drug associations, BNNR retrieves 145 drugs at top 1 rank,
while HGBI, DrugNet, MBiRW and DRRS have 111, 84, 136 and
134, respectively.
3.8 Computation time comparisons
In order to compare the computational efficiency of different meth-
ods, we have conducted a 10-fold cross-validation on the gold stand-
ard dataset, Cdataset and DNdataset. The running times of these
methods were obtained on a Linux server with CPU 2.30 GHz and
128 GB memory, which are shown in Supplementary Table S1. The
average running time of BNNR is more than HGBI and DrugNet
but less than MBiRW and DRRS on the gold standard dataset.
Although HGBI is much faster than the others, it yields the lowest






















































Fig. 7. The performance of all methods in predicting potential diseases for
new drugs on Cdataset. (a) PR curve of prediction results. (b) The number of
retrieved drugs for various rank thresholds































































































Fig. 8. The performance of all methods in predicting drug–disease association for 10-fold cross-validation on DNdataset. (a) ROC curve of prediction results. (b)
PR curve of predicting candidate diseases for drugs. (c) The number of correctly retrieved drug–disease associations for various rank threshold
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precision and AUC values. Moreover, compared to DrugNet on a
bigger dataset such as DNdataset, BNNR is more computationally
efficient.
4 Conclusions
This study has developed a novel method named BNNR for drug repo-
sitioning. BNNR not only can restrict all predicted matrix entry values
within a specific interval, but also exhibit robustness to tolerate poten-
tially noisy similarity calculations. The results of cross-validation and
de novo experiments have demonstrated that BNNR is an effective pre-
diction approach. Especially, comparing with the existing drug reposi-
tioning methods, BNNR yields both the best AUC value and the best
precision in most measures. Our case studies have confirmed the reli-
ability of the identified new drug–disease associations. In the future, we
plan to integrate drug–target information into the existing heteroge-
neous networks to further improve the prediction ability of BNNR.
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Fig. 9. The performance of all methods in predicting potential diseases for
new drugs on DNdataset. (a) PR curve of prediction results. (b) The number of
retrieved drugs for various rank thresholds
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